Molecular In My Pocket™…

ONCOLOGY: *Diagnostic Biomarkers in Bone & Soft Tissue Tumors – Part II*

Differentiation	Entity	Gene(s)	Type	Assays	Notes
Peripheral Nerve	Neurofibroma	*NF1*	Mutations (LOF)	NGS	Targeted kinase-inhibitor therapy available for patients with germline Neurofibromatosis Type I.
	Schwannoma	*NF2*	Mutations (LOF)	NGS	
	Granular cell tumor	*ATP6AP1*	Mutations (LOF)	NGS	*ATP6AP2* in a subset
	Malignant peripheral nerve sheath tumor	*EED, SUZ12*	Mutations (LOF)	NGS, IHC	80%; IHC: H3K27me3 negative
Uncertain Differentiation	Intramuscular myxoma	*GNAS*	Mutations (activating)	NGS	>90%
	Deep angiomyxoma	*HMGA2*	Rearrangements	FISH, IHC, NGS	IHC: HMGA2 nuclear expression
	Angiomatoid fibrous histiocytoma	*EWSR1-CREB1*	Fusions	FISH, NGS, RT-PCR	*FUS-ATF1* or *EWSR1-ATF1* in <10%
	Ossifying fibromyxoid tumor	*PHF1*	Fusions	NGS, NGS	*EP400* is most common partner. Alternate fusions in *BCOR, BCORL1, WWTR1* have been reported
	Soft tissue myoepithelial tumor	*EWSR1*	Fusions	FISH, NGS	~50%; *POU5F1* is most common partner, but many others reported. *FUS* instead of *EWSR1* in 10-20%.
	Soft tissue mixed tumor	*PLAG1*	Fusions	FISH, NGS	
	Hemosiderotic fibrolipomatous tumor	*TGFBR3, OGA*	Rearrangements	FISH	85%; Leads to overexpression of *FGF4* and *NPM3*
	Phosphaturic mesenchymal tumor	*FN1-FGFR1*	Fusions	FISH, NGS	50-60%, *FN1-FGF1* in rare cases
	Synovial sarcoma	*SS18-SSX1*	Fusions	FISH, NGS, RT-PCR	*SS18-SSX2* also common, rarely *SS18-SSX4*
	Epithelioid sarcoma	*SMARCB1*	Loss	IHC, NGS	IHC: INI-1 loss. EZH2-inhibitor therapy available (1)
	Extrarenal rhabdoid tumor	*SMARCB1*	Loss	IHC, NGS	IHC: INI-1 loss
	Alveolar soft part sarcoma	*ASPSCR1-TFE3*	Fusions	FISH, IHC, NGS	IHC: Nuclear TFE3
Uncertain Differentiation	Clear cell sarcoma of soft tissue	*EWSR1-ATF1*	Fusions	FISH, NGS	*EWSR1-CREB1* in a subset
	Extraskeletal myxoid chondrosarcoma	*EWSR1-NR4A3*	Fusions	FISH, NGS	*TAF15-NR4A3* in a subset
	Desmoplastic small round cell tumor	*EWSR1-WT1*	Fusions	FISH, IHC, NGS	IHC: C-terminal WT1 positive
	PEComa	*TSC2*	Mutations (LOF)	NGS	
		TFE3	Fusions	FISH, IHC, NGS	*SFPQ* is most common partner, but others reported
	Intimal sarcoma	*MDM2*	Amplification	FISH, NGS	
Undifferentiated Small Round Cell Sarcomas	Ewing sarcoma	*EWSR1-FLI1*	Fusions	FISH, NGS	*EWSR1-ERG* in ~10%, many other variant fusions reported
	Sarcoma with *EWSR1*-non-ETS fusions	*EWSR1-NFATC2*	Fusions	FISH, NGS	*FUS-NFATC2* in a subset
		EWSR1-PATZ1	Fusions	FISH, NGS	
	CIC-rearranged sarcoma	*CIC-DUX4*	Fusions	FISH, NGS	*CIC* with *FOXO4, LEUTX, NUTM1,* or *NUTM2A* rarely
	Sarcoma with *BCOR* alterations	*BCOR-CCNB3*	Fusions	FISH, IHC, NGS	IHC: CCNB3+
		BCOR	ITD	NGS, IHC	Infantile, rare cases with *YWHAE-NUTM2B*

Cartilage	Subungual exostosis	*IRS4*	Rearrangements		Possibly upregulates *IRS4* expression, breaks at *COL12A1* and *COL4A5*
	Enchondroma	*IDH1*	R132 mutations	NGS, PCR	*IDH2* R172 mutations less common
	Osteochondroma	*EXT1, EXT2*	Mutations (LOF)		Bilallelic inactivation
	Chondroblastoma	*H3F3B*	K36M	NGS, IHC	95%; IHC K36M-specific antibody
	Chondromyxoid fibroma	*GRM1*	Rearrangements		Highly upregulated expression often due to promoter swapping
	Synovial chondromatosis	*FN1-ACVR2A ACVR2A-FN1*	Fusions	FISH, NGS	
	Central chondrosarcoma	*IDH1*	R132 mutations	NGS, PCR	*IDH2* R172 mutations less common. IDH1-inhibitor therapy available (2)
	Mesenchymal chondrosarcoma	*HEY1-NCOA2*	Fusions	NGS, FISH	
Bone	Osteoid osteoma/osteoblastoma	*FOS*	Rearrangements	NGS, FISH	*FOSB* rearrangements less common
	Low-grade central osteosarcoma Parosteal osteosarcoma	*MDM2*	Amplification	FISH, IHC, NGS	
Other	Simple bone cyst	*EWSR1-NFATC2*	Fusions	NGS, FISH	Emerging data; also *FUS-NFATC2*
	Aneurysmal bone cyst	*CDH11-USP6*	Fusions	NGS, FISH	Many other partners reported
	Giant cell tumor of bone	*H3F3A*	G34W	NGS, IHC	90%, most of the rest have other G34 mutations
	Nonossifying fibroma	*KRAS, FGFR1*	Mutations (activating)	NGS	>80%
	Fibrous dysplasia	*GNAS*	R201 mutations	NGS	
Histiocytic	Langerhans cell histiocytosis	*BRAF*	V600E	NGS, PCR, IHC	Less commonly *MAP2K1*. Multiple targeted therapy options, dependent on alteration (3)
	Erdheim-Chester disease	*BRAF*	V600E	NGS, PCR, IHC	50-60%; also *KRAS, NRAS, ARAF, MAP2K1* in some. Multiple targeted therapy options, dependent on alteration (3)
	Rosai-Dorfman disease	MAPK pathway	Mutations (activating)	NGS, PCR, IHC	*BRAF, KRAS, NRAS, MAP2K1, ARAF*. Multiple targeted therapy options, dependent on alteration (3)
Emerging	Lipofibromatosis/lipofibromatosis-like neural tumor	*NTRK1, NTRK3*		FISH, IHC, NGS	Also reported: *RET, NTRK2, ROS1, ALK, MET, PDGFRB, BRAF*. NTRK-targeted therapy available
	S100+/CD34+ spindle cell neoplasms	*NTRK1, NTRK2, NTRK3*	Fusions	FISH, IHC, NGS	Similar *NTRK*-rearranged tumors are seen in the uterus as well as soft tissue. NTRK-targeted therapy available
	Round cell tumors with variable malignant potential and SMA expression	*ACTB-GLI1*	Fusions	FISH, NGS	Thought to be pericytomas originally
	ALK-positive histiocytosis	*KIF5B-ALK*	Fusions	FISH, IHC, NGS	

Note: Not all of the biomarkers above are diagnostically useful currently, and none (with rare exceptions) are completely specific.

Abbreviations: FISH: fluorescence in situ hybridization, GIST: gastrointestinal stromal tumor, IHC: immunohistochemistry, ITD: internal tandem duplication, LOF: loss-of-function, NGS: next-generation sequencing, PCR: polymerase chain reaction, RT-PCR: reverse transcriptase polymerase chain reaction, RTK: receptor tyrosine kinase

1. National Comprehensive Cancer Network. Clinical practice Guidelines in Oncology. Soft Tissue Sarcoma Version 2.2022 – May 17, 2022 NCCN.org. *accessed 6/27/2022*
2. National Comprehensive Cancer Network. Clinical practice Guidelines in Oncology. Bone Cancer Version 2.2022 – October 8, 2021 NCCN.org. *accessed 6/27/2022*
3. National Comprehensive Cancer Network. Clinical practice Guidelines in Oncology. Histiocytic Neoplasms Version 1.2022 – May 20, 2022 NCCN.org. *accessed 6/27/2022*

"Molecular in My Pocket" reference cards are educational resources created by the Association of Molecular Pathology (AMP) for laboratory and other health care professionals. The content does not constitute medical or legal advice, and is not intended for use in the diagnosis or treatment of individual conditions. See *www.amp.org* for the full "Limitations of Liability" statement.